1. Japan Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
JSR Corporation

JSR Corporation

JSCPY
JSR CorporationUS flagOther OTC
25.26
USD
+0.26
- -
51.00Market Cap
JSR Corporation
JSCPY
(Other OTC)

Recent

price

25.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
1,420.91
1,270.02
1,397.12
1,450.62
1,547.49
1,661.96
1,731.36
1,700.98
1,736.17
1,895.88
2,238.63
2,179.53
1,452.26
1,585.91
1,957.23
- -
1,916.13
Revenue per Share
56.36
55.86
113.07
109.46
126.13
106.1
128.19
105.87
135.17
149.31
140.62
104.38
-256.73
173.49
75.56
- -
7.36
Basic EPS, GAAP
136.73
240.16
222.53
120.13
198.78
149.52
220.58
211.7
50.73
28.24
-23.82
47.46
70.74
-136.47
-9.25
- -
-24.12
Free Cash Flow per Basic Share
32.14
28.99
29.05
32
33.16
35.67
39.15
45.05
50.06
50
55.02
60.27
59.98
64.98
70.8
- -
34.99
Dividend per Share
974.82
1,012.18
1,098.02
1,187.29
1,151.09
1,234.71
1,347.43
1,370.02
1,487.59
1,596.41
1,694.02
1,812.43
1,518.75
1,658.97
1,494.87
- -
1,497.55
Book Value per Share
948.33
1,002.38
1,061.48
1,149.03
1,288.96
1,390.95
1,501.27
1,532.27
1,599.35
1,715.67
1,658.96
1,677.43
1,382.85
1,267.48
958.62
- -
959.3
Tangible Book Value per Share
248
244
244
241
240
237
233
227
224
223
221
217
215
215
209
208
208
Basic Weighted Avg Shares
352,502
310,183
340,665
349,946
371,487
394,309
404,073
386,709
388,455
421,930
495,354
471,967
312,000
340,997
408,880
- -
397,766
Sales/Revenue/Turnover
8.61
6.52
11.48
10.28
9.48
9.15
9.42
8.9
9.08
10.25
9.03
6.95
11.19
12.79
7.16
- -
2.49
Operating Margin (%)
24,833
22,379
19,245
17,783
19,232
18,095
17,406
18,508
14,758
16,973
21,842
26,359
29,477
22,482
28,425
- -
31,384
Depreciation Expense
13,981
13,644
27,570
26,407
30,278
25,172
29,918
24,068
30,243
33,230
31,116
22,604
-55,155
37,303
15,784
- -
1,528
Net Income, GAAP
29.51
29.6
31.95
35.85
29.3
34.53
28.99
18.4
20.31
24.3
23.67
21.02
23.99
18.39
44.99
- -
48.21
Effective Tax Rate (%)
3.97
4.4
8.09
7.55
8.15
6.38
7.4
6.22
7.79
7.88
6.28
4.79
-17.68
10.94
3.86
- -
0.38
Profit Margin (%)
114,294
128,820
151,885
162,546
178,573
194,062
193,069
192,681
205,008
203,889
166,528
155,077
160,469
148,737
117,514
- -
106,419
Working Capital
- -
- -
- -
500
6,625
11,069
20,387
22,245
38,381
53,456
50,777
52,684
81,406
48,737
95,683
- -
92,490
LT Debt
241,985
250,700
264,116
282,357
315,733
337,259
364,673
365,842
376,364
411,615
440,359
437,412
370,736
414,739
380,935
- -
393,494
Total Equity
7.91
5.4
9.53
7.8
7.68
6.62
6.99
6.89
6.55
6.95
6.66
4.93
5.22
6.84
2.96
- -
0.92
Return on Invested Capital (%)
5.23
5.28
10.11
9.03
10.01
8.35
9.04
7.22
7.85
7.48
6.25
4.13
-10.91
7.34
3.33
- -
0.78
Return on Capital (%)
5.85
5.58
10.71
9.53
10.76
8.84
9.85
7.69
9.39
9.66
8.52
5.89
-15.35
10.92
4.72
- -
0.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
93,207
98,440
99,640
LT Borrowings
95,133
94,063
92,490
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
208
208
208
Market Capitalization
852,904
833,481
826,312

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
302,358
311,478
320,753
Cash, Cash Equivalents & STI
82,946
84,059
79,819
Accounts Receivable, Net
77,718
90,537
112,758
Inventories
119,705
122,482
111,575
Total Current Liabilities
200,787
212,226
214,334
Payables & Accruals
- -
- -
- -
ST Debt
93,207
98,440
99,640
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
82,310
85,905
88,380
84,403
340,997
2023
93,298
103,954
115,705
95,924
408,880
2024
85,046
95,734
121,062
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
37.98
43.62
82.9
- -
173.49
2023
27.09
43.51
23.36
- -
75.56
2024
-12.44
2.11
36.16
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
29.99
- -
34.99
- -
64.98
2023
35.51
- -
34.99
- -
70.8
2024
34.99
- -
- -
- -
- -
Similar Companies
Jai Corp Limited (JAICORPLTD.NS)
Berger Paints India Limited (BERGEPAINT.NS)
Tenma Corporation (7958.T)
Transpek Industry Limited (TRANSPEK.BO)
Binani Industries Limited (BINANIIND.BO)
Sakata INX Corporation (4633.T)
Business
JSR Corporation develops and manufactures advanced materials for semiconductors, displays, life sciences, and plastics. The company produces semiconductor materials including lithography materials such as photoresists and underlayers, chemical mechanical planarization slurries and cleaning solutions, and advanced packaging materials; display materials encompassing LCD panel materials and functional coatings as well as next-generation OLED materials; optical solutions featuring heat-resistant transparent resins and films, high-performance UV curable resins, and stereolithography systems; life sciences products and services comprising bioprocess materials like Protein A affinity chromatography resins including Amsphere A3 and A+, contract development and manufacturing organization services, contract research organization services, diagnostic reagents, and drug discovery support; and plastics such as ABS, AES, AS, and ASA resins for automotive parts, appliances, and building materials; alongside other offerings like Holter ECG monitoring services and emulsions. Founded in 1957 as Japan Synthetic Rubber Co., Ltd. and headquartered in Tokyo, Japan, JSR operates globally across Asia, Europe, and North America, serving electronics, automotive, pharmaceutical, and biotechnology sectors. In recent developments, JSR completed the acquisition of Yamanaka Hutech Corporation in August 2024 to expand its high-purity chemicals and semiconductor film-forming technologies; entered a cross-licensing and collaboration agreement with Lam Research and Inpria in September 2025 for advanced EUV resists and etching solutions; announced in October 2025 the sale of its chromatography business including Amsphere resins to MilliporeSigma; transferred its in vitro diagnostic business including Medical & Biological Laboratories and JSR Life Sciences to Tokuyama Corporation in 2025; merged with parent JICC-02 Ltd. in 2024 leading to delisting from the Tokyo Stock Exchange; and launched Amsphere A+ Protein A resin in September 2024 while forming alliances such as with Metagen Therapeutics for microbiome drug manufacturing.

Company News

APIChatGPT

  • reuters.com

    Exclusive: Japan state-backed fund considering sale of chipmaking materials maker JSR, sources say

  • zacks.com

    Lam Research Teams Up With JSR: Can it Lead in High-NA EUV?

  • prnewswire.com

    Lam Research and JSR Corporation/Inpria Corporation Enter Cross-Licensing, Collaboration Agreement to Advance Semiconductor Manufacturing

  • seekingalpha.com

    Essential Japanese Semi Companies For The Reshoring Age

  • zacks.com

    4 Top Stocks to Ride the Upturn in Chemical Plastics Industry